Organogenesis (ORGO) Stock Price, News & Analysis

Company Overview

Organogenesis Holdings Inc. (NASDAQ: ORGO) is a regenerative medicine company that develops, manufactures and commercializes advanced products designed to help repair and restore damaged tissue. Its principal business areas are advanced wound care and surgical and sports medicine, with products intended for use by hospitals, wound-care centers, physicians and other health care providers.

The company’s advanced wound-care portfolio includes Apligraf, a living cellular skin substitute used in the treatment of certain chronic wounds, as well as Dermagraft, PuraPly and other biologic and synthetic products. These offerings are designed to support wound closure, tissue regeneration and infection management in conditions such as diabetic foot ulcers, venous leg ulcers and other complex wounds.

Organogenesis also provides products for surgical, orthopedic and sports-medicine applications, including biologic matrices and tissue-repair solutions used in procedures involving soft tissue and other musculoskeletal structures. The company was founded in 1985 and is headquartered in Canton, Massachusetts. Its products are marketed primarily in the United States through health care providers and specialized sales channels.

Key Stats

• Today's Range: $1.29 to $1.35
• 50-Day Range: $1.29 to $2.52
• 52-Week Range: $1.28 to $7.08
• Volume: 608,728 shs
• Average Volume: 679,566 shs
• Market Capitalization: $172.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.33
• Consensus Rating: Reduce

Organogenesis Stock Analysis - MarketRank™

Organogenesis scored higher than 33% of companies evaluated by MarketBeat, and ranked 731st out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Organogenesis has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Organogenesis has a consensus price target of $4.33, representing about 223.4% upside from its current price of $1.34.

Amount of Analyst Coverage

Organogenesis has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Organogenesis is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organogenesis is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Organogenesis has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.51% of the float of Organogenesis has been sold short.

Short Interest Ratio / Days to Cover

Organogenesis has a short interest ratio ("days to cover") of 18.82, which indicates bearish sentiment.

Change versus previous month

Short interest in Organogenesis has recently decreased by 0.90%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organogenesis does not currently pay a dividend.

Dividend Growth

Organogenesis does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

6 people have searched for ORGO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added Organogenesis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Organogenesis insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.80% of the stock of Organogenesis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

49.57% of the stock of Organogenesis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/07/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ORGO
• CIK: 1661181
• Web: organogenesis.com
• Phone: (781) 575-0775
• Fax: N/A
• Employees: 854
• Year Founded: 1985

Price Target and Rating

• Average Price Target for Organogenesis: $4.33
• High Price Target: $8.00
• Low Price Target: $2.00
• Potential Upside/Downside: +223.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $37.03 million
• Net Margins: -19.94%
• Pretax Margin: -7.60%
• Return on Equity: -23.89%
• Return on Assets: -11.13%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 3.52
• Quick Ratio: 3.00

Sales & Book Value

• Annual Sales: $564.17 million
• Price / Sales: 0.31
• Cash Flow: $0.67 per share
• Price / Cash Flow: 1.99
• Book Value: $2.36 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 128,680,000
• Free Float: 104,484,000
• Market Cap: $172.43 million
• Optionable: Optionable
• Beta: 1.27